EP
VRTX icon

Essential Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Essential Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$188K Buy
378
+340
+895% +$151K 0.09% 245
2026
Q1 		$17K Buy
38
+22
+138% +$10.3K 0.01% 998
2025
Q4 		$7.25K Buy
16
+4
+33% +$1.72K ﹤0.01% 1279
2025
Q3 		$4.7K Sell
12
-20
-63% -$8.36K ﹤0.01% 1447
2025
Q2 		$14.2K Buy
+32
New +$14.7K 0.01% 757

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Essential Partners's VRTX Position: Q2 2026 in Review

Essential Partners increased its Vertex Pharmaceuticals (VRTX) stake by 895% in Q2 2026, buying an estimated $151K and bringing the position to 378 shares worth $188K. The position accounts for 0.09% of the portfolio, ranked #245.

Essential Partners first reported a position in VRTX in Q2 2025 and has held it in 5 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Essential Partners held 378 shares of Vertex Pharmaceuticals worth $188K as of Q2 2026.
  • Essential Partners bought 340 Vertex Pharmaceuticals shares in Q2 2026, an estimated $151K.
  • Vertex Pharmaceuticals made up 0.09% of Essential Partners's portfolio in Q2 2026, its #245 holding.
  • Essential Partners first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.